GlaxoSmithKline plc (LON:GSK) insider Patrick Vallance sold 20,000 shares of the firm’s stock in a transaction dated Monday, December 18th. The stock was sold at an average price of GBX 1,310 ($17.63), for a total value of £262,000 ($352,624.50).

Patrick Vallance also recently made the following trade(s):

  • On Thursday, November 9th, Patrick Vallance purchased 10 shares of GlaxoSmithKline stock. The shares were purchased at an average cost of GBX 1,364 ($18.36) per share, for a total transaction of £136.40 ($183.58).

GlaxoSmithKline plc (GSK) traded up GBX 9 ($0.12) during trading on Monday, hitting GBX 1,304 ($17.55). The company had a trading volume of 9,197,631 shares, compared to its average volume of 10,070,000. GlaxoSmithKline plc has a 12-month low of GBX 1,270 ($17.09) and a 12-month high of GBX 1,724.50 ($23.21).

GlaxoSmithKline (LON:GSK) last posted its quarterly earnings results on Wednesday, October 25th. The company reported GBX 32.50 ($0.44) earnings per share for the quarter, beating the Zacks’ consensus estimate of GBX 31.80 ($0.43) by GBX 0.70 ($0.01). GlaxoSmithKline had a return on equity of 461.88% and a net margin of 17.79%. The firm had revenue of GBX 784.30 billion for the quarter.

The firm also recently declared a dividend, which will be paid on Thursday, January 11th. Investors of record on Thursday, November 9th will be paid a GBX 19 ($0.26) dividend. The ex-dividend date is Thursday, November 9th. This represents a dividend yield of 1.41%.

GSK has been the topic of several research analyst reports. reaffirmed a “buy” rating and set a GBX 1,970 ($26.51) price target on shares of GlaxoSmithKline in a research report on Wednesday, September 13th. Liberum Capital reaffirmed a “buy” rating and set a GBX 1,900 ($25.57) price target on shares of GlaxoSmithKline in a research report on Wednesday, August 30th. Jefferies Group cut their price target on GlaxoSmithKline from GBX 1,900 ($25.57) to GBX 1,750 ($23.55) and set a “buy” rating on the stock in a research report on Thursday, August 24th. Berenberg Bank reaffirmed a “buy” rating and set a GBX 1,835 ($24.70) price target on shares of GlaxoSmithKline in a research report on Tuesday, September 19th. Finally, Goldman Sachs Group reaffirmed a “buy” rating and set a GBX 1,900 ($25.57) price target on shares of GlaxoSmithKline in a research report on Tuesday, October 17th. Three investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have given a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of GBX 1,562.86 ($21.03).

COPYRIGHT VIOLATION NOTICE: This story was first posted by American Banking News and is the property of of American Banking News. If you are accessing this story on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/12/18/insider-selling-glaxosmithkline-plc-gsk-insider-sells-20000-shares-of-stock.html.

About GlaxoSmithKline

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Insider Buying and Selling by Quarter for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.